



Radius Health, Inc.
Investor Relations Department
950 Winter St, North Building 1st Floor
North Building 1st Floor
Waltham, MA 02451
United States

[Visit IR website](#)
[Sign-up for Email alerts](#)

NASDAQ: RDUS

Last Trade:	27.91
Trade Time:	4:00 PM ET Jul 20, 2018
Change:	-0.55 (-1.933%)
Day Range	27.74 - 28.48
52-Week Range	24.66 - 45.90
Volume	454,085

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

Radius is a science-driven fully integrated biopharmaceutical company that is committed to developing and commercializing innovative endocrine therapeutics in the areas of osteoporosis and oncology. Radius' lead product, TYMLOS® (abaloparatide) injection was approved by the U.S. Food and Drug Administration for the treatment of postmenopausal women with osteoporosis at high risk for fracture. The Radius clinical pipeline includes investigational abaloparatide injection for potential use in the treatment of men with osteoporosis; an investigational abaloparatide patch f... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

- Jul 16, 2018*
[Radius Health Reports Inducement Grant Under Nasdaq Listing Rule 5635\(c\)\(4\)](#)
- Jul 16, 2018*
[Radius Health Strengthens Senior Management Team with Appointment of Chhaya Shah as Senior Vice President of Technical Operations](#)
- Jun 7, 2018*
[Radius Health to Present at the Goldman Sachs 39th Annual Global Healthcare Conference](#)
- Jun 5, 2018*
[Radius to Host Investor Day on June 8, 2018](#)
- May 11, 2018*
[Radius Health to Present at the Bank of America Merrill Lynch 2018 Annual Healthcare Conference](#)

Financials [\[View all \]](#)

- [First Quarter Financial Results](#)
- Mar 1, 2018*
[Annual Report \(10-K\)](#)
- Apr 20, 2018*
[Proxy Statement \(DEF 14A\)](#)
- May 10, 2018*
[Quarterly Report \(10-Q\)](#)
- Nov 2, 2017*
[Quarterly Report \(10-Q\)](#)
- Aug 4, 2017*
[Quarterly Report \(10-Q\)](#)